MXPA99010523A - Metodos para mejorar el funcionamiento del tractogastrointestinal superior. - Google Patents
Metodos para mejorar el funcionamiento del tractogastrointestinal superior.Info
- Publication number
- MXPA99010523A MXPA99010523A MXPA99010523A MX9910523A MXPA99010523A MX PA99010523 A MXPA99010523 A MX PA99010523A MX PA99010523 A MXPA99010523 A MX PA99010523A MX 9910523 A MX9910523 A MX 9910523A MX PA99010523 A MXPA99010523 A MX PA99010523A
- Authority
- MX
- Mexico
- Prior art keywords
- upper gastrointestinal
- methods
- glp
- gastrointestinal tract
- tissue
- Prior art date
Links
- 210000002438 upper gastrointestinal tract Anatomy 0.000 title abstract 5
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 5
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 5
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 5
- 239000000813 peptide hormone Substances 0.000 abstract 3
- 230000002496 gastric effect Effects 0.000 abstract 2
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 102400000321 Glucagon Human genes 0.000 abstract 1
- 108060003199 Glucagon Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000003238 esophagus Anatomy 0.000 abstract 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
- 229960004666 glucagon Drugs 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La invencion se refiere a peptidos relacionados son glucagon y a su uso para al prevencion o el tratamiento de trastornos que involucran el tracto gastrointestinal superior, incluyendo el esofago y el estomago. Particularmente, se ha demostrado ahora que GLP-2 y agonistas peptidicos de GLP-2 pueden provocar la proliferacion del tejido del tracto gastrointestinal superior. Asi, la invencion ofrece metodos para la proliferacion de tejido del tracto gastrointestinal superior en un paciente que lo requiere. Ademas los metodos de la presente invencion son utiles para tratar o prevenir condiciones inflamatorias del tracto gastrointestinal superior, incluyendo enfermedades inflamatorias. GLP-2 estimula el crecimiento de tejido gastrointestinal superior cuando se administra en combinacion con otras hormonas de peptido. La presente invencion ofrece ademas composiciones farmaceuticas de GLP-2 con al menos otra hormona de peptido, metodos para incrementar el crecimiento del tejido gastrointestinal superior y prevenir trastornos gastrointestinales mediante el incremento de los niveles sericos de GLP-2 y al menos otra hormona del peptido, asi como un conjunto de elementos para practicar los metodos de la presente invencion.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4675497P | 1997-05-16 | 1997-05-16 | |
GBGB9715481.9A GB9715481D0 (en) | 1997-07-23 | 1997-07-23 | Methods of enhancing functioning of the upper gastrointestinal tract |
US09/059,504 US6051557A (en) | 1997-05-16 | 1998-04-13 | Methods of enhancing functioning of the upper gastrointestinal tract |
PCT/CA1998/000497 WO1998052600A1 (en) | 1997-05-16 | 1998-05-15 | Methods of enhancing functioning of the upper gastrointestinal tract |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99010523A true MXPA99010523A (es) | 2004-09-01 |
Family
ID=27268946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA99010523A MXPA99010523A (es) | 1997-05-16 | 1998-05-15 | Metodos para mejorar el funcionamiento del tractogastrointestinal superior. |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0981362B1 (es) |
JP (2) | JP4699576B2 (es) |
CN (1) | CN1264307B (es) |
AT (1) | ATE253375T1 (es) |
AU (1) | AU746633B2 (es) |
BR (1) | BR9808804A (es) |
CA (1) | CA2289652C (es) |
DE (1) | DE69819488T2 (es) |
DK (1) | DK0981362T3 (es) |
ES (1) | ES2210756T3 (es) |
HK (1) | HK1030160A1 (es) |
MX (1) | MXPA99010523A (es) |
PT (1) | PT981362E (es) |
WO (1) | WO1998052600A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69819488T2 (de) * | 1997-05-16 | 2004-08-26 | 1149336 Ontario Inc., Toronto | Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes |
GB9905416D0 (en) * | 1999-03-09 | 1999-05-05 | Allelix Biopharma | Small molecules having GLP-2 like activity |
US20030040478A1 (en) * | 1999-12-08 | 2003-02-27 | Drucker Daniel J | Chemotherapy treatment |
EP1970072A1 (en) * | 2000-09-18 | 2008-09-17 | Sanos Bioscience A/S | Use of GLP-2 peptides for the treatment of hyperparathyroidism |
US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
US7411039B2 (en) | 2002-10-14 | 2008-08-12 | Novo Nordisk A/S | GLP-2 compounds, formulations, and uses thereof |
EP1809318B1 (en) | 2004-11-01 | 2013-06-12 | NPS Pharmaceuticals, Inc. | Treatment of short bowel syndrome patients with colon-in-continuity |
UA95235C2 (en) | 2005-05-04 | 2011-07-25 | Зииланд Фарма А/С | Glucagon-like-peptide-2 (glp-2) analogues |
CN101573376B (zh) * | 2006-11-08 | 2013-11-06 | 西兰制药公司 | 选择性胰高血糖素样肽-2(glp-2)类似物 |
US20110171164A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
CA2846680C (en) * | 2010-08-30 | 2019-06-25 | Takeda Gmbh | Solid phase synthesis of h[gly2]glp-2 |
CA2872315A1 (en) | 2012-05-03 | 2013-11-07 | Zealand Pharma A/S | Glucagon-like-peptide-2 (glp-2) analogues |
CN106167789B (zh) * | 2015-05-21 | 2020-08-04 | 中国科学院上海营养与健康研究所 | 低氧处理的间充质干细胞及其应用 |
SG11201903938XA (en) | 2016-12-09 | 2019-05-30 | Zealand Pharma As | Acylated glp-1/glp-2 dual agonists |
CN108273038B (zh) * | 2018-03-16 | 2019-03-19 | 中国人民解放军军事科学院军事医学研究院 | 防治肠型放射病的药物组合物 |
CN110226566A (zh) * | 2019-07-12 | 2019-09-13 | 南京中医药大学 | 一种放射性口腔黏膜炎动物模型的造模方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK27885A (da) * | 1985-01-22 | 1986-07-23 | Novo Industri As | Fremstilling af peptider |
US5990077A (en) * | 1995-04-14 | 1999-11-23 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
AU733857B2 (en) * | 1996-04-12 | 2001-05-31 | 1149336 Ontario Inc. | Glucagon-like peptide-2 analogs |
DE69714085T2 (de) * | 1996-12-06 | 2002-11-14 | Amgen Inc | Verwendung eines kgf-proteinproduktes und eines glp-2 proteinproduktes für die herstellung eines medikamentes |
US5952301A (en) * | 1996-12-10 | 1999-09-14 | 1149336 Ontario Inc. | Compositions and methods for enhancing intestinal function |
DE69819488T2 (de) * | 1997-05-16 | 2004-08-26 | 1149336 Ontario Inc., Toronto | Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes |
-
1998
- 1998-05-15 DE DE69819488T patent/DE69819488T2/de not_active Expired - Lifetime
- 1998-05-15 AT AT98922546T patent/ATE253375T1/de active
- 1998-05-15 ES ES98922546T patent/ES2210756T3/es not_active Expired - Lifetime
- 1998-05-15 MX MXPA99010523A patent/MXPA99010523A/es active IP Right Grant
- 1998-05-15 DK DK98922546T patent/DK0981362T3/da active
- 1998-05-15 CN CN988073307A patent/CN1264307B/zh not_active Expired - Fee Related
- 1998-05-15 AU AU75163/98A patent/AU746633B2/en not_active Ceased
- 1998-05-15 WO PCT/CA1998/000497 patent/WO1998052600A1/en active IP Right Grant
- 1998-05-15 BR BR9808804-1A patent/BR9808804A/pt not_active Application Discontinuation
- 1998-05-15 EP EP98922546A patent/EP0981362B1/en not_active Expired - Lifetime
- 1998-05-15 CA CA2289652A patent/CA2289652C/en not_active Expired - Fee Related
- 1998-05-15 JP JP54974198A patent/JP4699576B2/ja not_active Expired - Fee Related
- 1998-05-15 PT PT98922546T patent/PT981362E/pt unknown
-
2001
- 2001-02-20 HK HK01101222.7A patent/HK1030160A1/xx not_active IP Right Cessation
-
2009
- 2009-07-22 JP JP2009171401A patent/JP2009280598A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1264307B (zh) | 2013-10-30 |
CN1264307A (zh) | 2000-08-23 |
ES2210756T3 (es) | 2004-07-01 |
BR9808804A (pt) | 2001-09-18 |
HK1030160A1 (en) | 2001-04-27 |
DE69819488T2 (de) | 2004-08-26 |
JP2002502369A (ja) | 2002-01-22 |
AU7516398A (en) | 1998-12-11 |
ATE253375T1 (de) | 2003-11-15 |
CA2289652C (en) | 2012-02-28 |
DE69819488D1 (de) | 2003-12-11 |
EP0981362B1 (en) | 2003-11-05 |
DK0981362T3 (da) | 2004-03-15 |
JP4699576B2 (ja) | 2011-06-15 |
WO1998052600A1 (en) | 1998-11-26 |
EP0981362A1 (en) | 2000-03-01 |
AU746633B2 (en) | 2002-05-02 |
WO1998052600A9 (en) | 2000-03-09 |
JP2009280598A (ja) | 2009-12-03 |
PT981362E (pt) | 2004-03-31 |
CA2289652A1 (en) | 1998-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE233096T1 (de) | Zusammensetzungen und methoden zur steigerung der darmfunktion | |
HK1030160A1 (en) | Methods of enhancing functioning of the upper gastrointestinal tract | |
Nishi et al. | The soybean β-conglycinin β 51–63 fragment suppresses appetite by stimulating cholecystokinin release in rats | |
Wormsley | Response to duodenal acidification in man: III. Comparison with the effects of secretin and pancreozymin | |
FI972744A0 (fi) | Aminohappokokoonpanoja ja niiden käyttö kliinisessä ravinnossa | |
MXPA05002991A (es) | Analogos de ghrh. | |
CA2246733A1 (en) | Use of a pharmaceutical composition comprising an appetite-suppressing peptide | |
WO2003000242A3 (en) | Method for the treatment of lymphedema using guaifenesin | |
MXPA04005053A (es) | Metodos y composiciones para tratar lesiones del epitelio respiratorio. | |
ATE338771T1 (de) | Antagonisten des intestinotrophen glp-2 peptides | |
EP1792915A3 (en) | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension | |
HK1080363A1 (en) | Use of compounds having the biological activity ofvasoactive intestinal peptide for the treatment o f sarcoidosis | |
WO2005072277A3 (en) | Amidated parathyroid hormone fragments and uses thereof | |
BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
JP2013501736A (ja) | 神経変性の修復方法 | |
Kitchen et al. | Intestinal growth in parenterally‐fed rats induced by the combined effects of glucagon‐like peptide 2 and epidermal growth factor | |
Walsh et al. | Localization of bombesin-like immunoreactivity (BLI) in gut and brain of rat | |
Kamakura et al. | Colonic Delivery of Nutrients for Sustained and Prolonged Release of Gut Peptides: A Novel Strategy for Appetite Management | |
Variyam et al. | Degradation of gut mucins. Carbohydrate side chains protect the polypeptide core from pancreatic elastase | |
Yoshinaga et al. | Stimulation of pancreatic growth: Distal small bowel resection mediated by increased levels of cholecystokinin | |
Volpicelli et al. | Isolated right sided colitis associated with ampicillin and amoxicillin. An early stage of pseudomembranous colitis (PMC)? | |
Schönfeld et al. | Glucose-dependent effects of pancreastatin on insulin and glucagon release | |
Vérine et al. | Hypercalcemia vomiting: An experimental study in the dog | |
JP2003509336A (ja) | 物質のpnsにおける新規使用 | |
Thimister | Physiological aspects of gallbladder motility and pancreatic enzyme secretion in humans: studies on plasma cholecystokinin, intraduodenal bile salts, protease activity, and nerve-gut interaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |